Shield Therapeutics plc (LON:STX)‘s stock had its “buy” rating reiterated by equities researchers at FinnCap in a research note issued to investors on Tuesday. They presently have a GBX 265 ($3.49) target price on the stock. FinnCap’s price objective points to a potential upside of 94.14% from the company’s current price.

A number of other research firms also recently weighed in on STX. Peel Hunt reissued a “buy” rating and set a GBX 220 ($2.89) target price on shares of Shield Therapeutics plc in a research report on Wednesday, November 8th. Liberum Capital reissued a “buy” rating and set a GBX 245 ($3.22) target price on shares of Shield Therapeutics plc in a research report on Tuesday, October 10th.

Shield Therapeutics plc (LON:STX) traded down GBX 10 ($0.13) during trading hours on Tuesday, reaching GBX 136.50 ($1.80). 6,463 shares of the company’s stock were exchanged, compared to its average volume of 2,815. Shield Therapeutics plc has a twelve month low of GBX 143 ($1.88) and a twelve month high of GBX 173.50 ($2.28).

COPYRIGHT VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at

About Shield Therapeutics plc

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.

Receive News & Ratings for Shield Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics plc and related companies with's FREE daily email newsletter.